Drug intelligence / Profile preview

Neukast

Development stage: Phase 1
Lead developer: Amgen
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous, Intravenous

Overview

Neukast is a recombinant granulocyte colony-stimulating factor (G-CSF) marketed by Eurolab as a generic version of filgrastim. It is indicated for the treatment and prevention of chemotherapy-induced neutropenia and other neutropenic conditions in oncology patients. By binding to the G-CSF receptor (CSF3R), Neukast stimulates the production, maturation, and activation of neutrophils in the bone marrow, thereby reducing the duration and severity of neutropenia and the risk of associated infections. It is typically administered via subcutaneous injection or intravenous infusion and serves as a supportive care medicine in oncology.

Brand names: NeukastNeukast 480Neukast480Neukast-480
Other names: filgrastimgeneric filgrastim

Targets

CSF3R (Granulocyte colony-stimulating factor receptor)

Beyond the preview

Go deeper on Neukast.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neukast.

Explore the full profile